5 minAs the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting approaches, the U.S. FDA has announced an extension of the Prescription Drug User Fee Act (PDUFA) target action date for the New Drug Application (NDA) of camizestrant—a next-generation oral selective estrogen receptor degrader (SERD)—in combination with a CDK4/6 inhibitor for the first-line treatment of HR+/HER2- advanced breast cancer.
This extension is more than a procedural delay; it reflects the regulatory agency’s rigorous scrutiny of a frontier clinical strategy: early molecular-level intervention. The FDA has requested additional analyses from AstraZeneca, specifically focusing on the correlation between circulating tumor DNA (ctDNA) clearance and long-term clinical benefit. These pivotal data are slated for presentation at ASCO 2026.
The SERENA-6 Study: Driving Progression-Free Survival (PFS)
The core evidence supporting this NDA stems from the Phase 3 SERENA-6 trial (NCT04964934). The study explores a groundbreaking "treatment switch" strategy: for HR+/HER2- advanced breast cancer patients, should therapy be switched immediately upon detecting an ESR1 mutation (molecular progression) even if diagnostic imaging indicates stable disease?
According to published data, the SERENA-6 study demonstrated robust PFS benefits:
-
Key Findings: Among patients with emergent ESR1 mutations, those who switched to "camizestrant + CDK4/6 inhibitor" (n=157) achieved a median PFS of 16.0 months (95% CI, 12.7–18.2). In contrast, the control group (n=158) continuing with "aromatase inhibitor + CDK4/6 inhibitor" had a median PFS of only 9.2 months (HR, 0.44; 95% CI, 0.31–0.60; P < .00001).
-
Updated Evidence: Data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) further confirmed these results, with the camizestrant switch arm showing a median PFS of 16.6 months versus 9.2 months in the control regimen (HR, 0.46; P < .00001).
Jane L. Meisel, MD, of Emory University School of Medicine, noted: "If approved, this will end up changing the paradigm of what we do for patients. It would mean we should presumably be checking for ESR1 mutations at baseline and then potentially making a switch based on molecular markers, as opposed to waiting for imaging to indicate disease progression."
ODAC’s "Cautious Logic": The Core Scientific Controversy
Despite receiving FDA Breakthrough Therapy Designation in May 2025, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6-3 in April 2026 against the clinically meaningful benefit of switching therapy based on molecular progression before radiographic evidence of disease.
The core controversies include:
-
Lack of Crossover Design: The SERENA-6 trial did not allow patients in the control arm to cross over to the investigative therapy upon radiographic progression. Experts, such as Alexis Ann LeVee, MD (UCLA Health), argue that without this, the trial cannot definitively answer whether early switching at molecular progression is superior to switching upon radiographic progression.
-
Immature Overall Survival (OS): OS data remain immature, making it difficult to determine if this "early switch" strategy provides long-term survival advantages.
-
Clinical Endpoints: Beyond PFS, regulators remain focused on patient-reported outcomes (PROs) and whether this early intervention truly aligns with the clinical needs and quality of life of patients.
Expert Perspective: Science vs. Strategy
Sarah Sammons, MD (Dana-Farber Cancer Institute), a proponent of the SERENA-6 strategy, argues that while the trial design has limitations, it represents a crucial direction in oncology: intercepting biology and resistance before it is too late. "Any paradigm-shifting trial deserves scrutiny," Dr. Sammons stated. "However, I believe this is a strategy our patients could benefit from, as they are often eager to stay ahead of resistance rather than waiting until scans deteriorate and their condition worsens before changing therapy."
Global Regulatory Status and Future Outlook
While the FDA remains cautious, global momentum is building. On May 22, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of camizestrant in this setting. Additionally, the drug has already been approved in Saudi Arabia and the United Arab Emirates.
For the global breast cancer community, the ctDNA clearance data to be revealed at ASCO 2026 will serve as a critical litmus test. If these findings further solidify the logical link between molecular intervention and long-term clinical benefit, camizestrant may overcome its current regulatory hurdles.
About Camizestrant
Camizestrant is an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist currently in Phase III trials for HR-positive breast cancer. Unlike traditional estrogen receptor modulators, camizestrant induces ER degradation and fully blocks the signaling pathway to overcome endocrine therapy resistance.
AstraZeneca is conducting a robust clinical program, including the SERENA-6, SERENA-4, CAMBRIA-1, and CAMBRIA-2 trials, to evaluate the safety and efficacy of camizestrant as both monotherapy and in combination with CDK4/6 inhibitors (such as palbociclib, ribociclib, and abemaciclib).
Preclinical models have shown significant anti-cancer activity across a range of ER-activating mutations. In the Phase II SERENA-2 trial, camizestrant demonstrated statistically significant and clinically meaningful improvements in PFS versus fulvestrant, particularly in patients with ESR1 mutations. Furthermore, the Phase I SERENA-1 trial confirmed that camizestrant is well-tolerated and possesses a promising anti-tumor profile when administered alone or in combination with widely used CDK4/6 inhibitors, offering a high-potential therapeutic option for patients with HR+ breast cancer who face significant unmet needs.
